New research from The Wistar Institute's Salvino lab, led by professor Joseph Salvino, Ph.D., has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 treatments that—according to preclinical testing—effectively inhibit COVID-19 and synergize with existing anti-COVID therapies.
